Clinical Trial

Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2024 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the efficacy and safety of Cadonilimab (AK104) combined with chemotherapy and bevacizumab as first-line treatment for patients with RAS mutated or right sided-metastatic MSS colorectal cancer
Trial Details
NCT Number NCT06566755
Lead Sponsor Caigang Liu
Conditions Colorectal Cancer
Enrollment 30 participants
Start Date 2024-02-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-22